A peptide (C13) corresponding to the last 13 amino acids of the carboxyl terminus of human platelet factor IV was found to be antibacterial. Amino acid substitutions predicted to disrupt either the amphipathic or a-helical nature of C13 rendered the peptide inactive. Antibacterial activity was demonstrated in normal human serum on bacteria which had been previously exposed to low levels of cefepime, a f-lactam antibiotic. Peptide analogues were examined for more potent antibacterial activity in an antibacterial assay that employed normal human serum and low levels of cefepime. A peptide analogue (C18G) with 80-fold more antibacterial activity than C13 was identified. Studies in C8-deficient sera confirmed an essential role of human serum complement for optimal antibacterial activity. Additional studies showed low levels of cefepime, although not essential, enhanced the antibacterial activity of C18G. Animal protection experiments demonstrated that either peptide C18G or an analogue with all D amino acids (C18X) significantly increased the survival of neutropenic mice when coadministered with a low level of cefepime. This work has resulted in the identification of a new group of antibacterial peptides. (J. Clin. Invest. 1992. 90:447455.)
Introduction
Bacterial infections in the neutropenic patient remain a major cause of morbidity and mortality despite rigorous antibiotic treatment ( I ). Efforts to improve the clinical response to antibiotic treatment in these patients include therapies intended to augment the host immune system (2) (3) (4) as well as the search for more efficacious antibacterial agents. In the past, new antibacterial agents have either been more bactericidal (5) and less likely to elicit bacterial resistance, or demonstrated more favorable pharmacokinetic properties (6) . However, to our knowledge, no new antibacterial agents have been specifically de- signed to augment the host immune system in the eradication ofbacterial infections. It is becoming increasingly clear that the host immune system plays an important role in the eradication ofbacterial infections during antibiotic therapy (5) . Retrospective clinical analyses have clearly shown that antibiotics are more successful when an intact host defense system is present ( 1 ) . In addition, both in vitro (7, 8) and in vivo studies (9) have confirmed that antibiotic-altered bacteria are significantly more susceptible to polymorphonuclear cell-mediated phagocytosis, a major component of the host immune system involved with bacterial removal. It has been proposed that antibiotic injured bacteria may be adequately handled by immunosufficient hosts but not by immunocompromised patients (5) . This may account for some ofthe antibiotic treatment failures in these patients. We are attempting to improve the clinical response to antibiotic treatment for neutropenic patients by investigating therapies that would kill antibiotic-injured bacteria.
Recently, it has been shown that low concentrations of flactam antibiotics may render bacteria more susceptible to serum-mediated killing (10, 11) . This is a potentially useful effect for the immunocompromised patient in that serum-mediated killing is the major host defense system for these patients. We have shown that the terminal complement complex was necessary for enhanced antibiotic killing and the f3-lactamaltered bacterial cell surface allowed more terminal complement complex deposition ( 12) . The data suggested that ,B-lactam-altered bacteria might be more susceptible to other agents, which in a mechanism similar to complement, need to gain access to the bacterial inner membrane for bactericidal activity. To test this hypothesis, the susceptibility of,B-lactam-altered Escherichia coli to a recently described ( 13) antimicrobial peptide designated magainin 2 was examined ( 14) . It was demonstrated that ,B-lactam-altered bacteria were significantly more susceptible to magainin 2 both in vitro and in vivo mouse protection experiments. The data suggested that therapies designed to kill antibiotic-injured bacteria might improve the clinical response to antibiotic treatment for the neutropenic patient. We proposed that peptide killing of antibiotic-injured bacteria could theoretically mimic the host role in antibiotic therapy of immune-deficient patients.
The possibility that antibacterial peptides could improve standard antibiotic therapy for the neutropenic patient prompted us to examine other potentially useful peptides. Examination of the literature revealed that a common theme for several different antimicrobial peptides was a tendency to form an amphipathic a-helical conformation in a hydrophobic environment ( 15) . This conformation may promote interaction of the peptide with the bacterial membrane ( 16) . Independently, a variety of human proteins have been shown to contain amphipathic a-helix sequences, which in a similar fashion are believed to facilitate the protein's interaction with membranes ( 17, 18) . A peptide was synthesized which corresponded to the last 13 amino acids found at the carboxyl terminus of platelet factor IV (PF4).' In this report we demonstrate that this pep-tide has antibacterial activity against cefepime-altered bacteria when examined in normal human serum. The unique requirement for both antibiotic and serum for antibacterial activity of the carboxyl terminus of PF4 was used as a basis to examine peptide analogues for antibacterial activity. This process of screening for antibacterial agents deviates significantly from the classic approach of looking for activity in a broth or mediabased system. Therefore, we additionally report the in vitro and in vivo evaluation of a more potent synthetic peptide obtained by this methodology.
Methods
Reagents and buffers. The following buffers were used: gelatin-veronal buffer with the addition of 0.1% dextrose (GVB "; [19] ) and phosphate-buffered saline (PBS). Cefepime (7- " to a volume of0.2 ml. Cefepime, when present, was added to the serum mixture before the addition of bacteria. The total reaction mixture was 0.25 ml. The number of bacteria added to serum was determined by adding 0.05 ml of the bacterial suspension to a tube containing only GVB++ and plating at the beginning ofthe assay. The reaction mixtures were then rotated at 370C for 3 h. Samples were removed at intervals and diluted appropriately for plate count analysis (in triplicate) by the pour plate method (22) using trypticase soy agar. The number of colony forming units was determined after overnight incubation.
The potential for error due to drug carryover effects was eliminated by inclusion ofappropriate controls. Inclusion ofpeptide and cefepime in H-NHS-and C8-deficient sera eliminated the need for drug removal procedures because significant antibacterial activity was detected only in NHS-and C8-replenished sera.
Red blood cell hemolysis assay. The hemolytic activity of the antimicrobial peptides was examined as described by Geoffroy et al. (23) except that red blood cells were added to various concentrations of peptides in GVB`+ buffer without the addition of bovine serum albumin. In addition, samples were centrifuged for 5 min at 1,000 g to remove cell debris before the optical density at 541 nm was recorded. A IN.) . Examination of blood revealed that the level ofcirculating leukocytes declined to 10% of normal by the 5th day after injection and remained depressed for the following 2 days. Mice were challenged intraperitoneally with a log-phase bacterial suspension in PBS (0.2 ml) on the 4th day after cyclophosphamide administration. Probit analysis (24) was used to determine the LD90 for E. coli H 16 and E. coli AP. For therapeutic protection experiments mice were administered one LD90 which was 2 x 104 cfu for E. coli H 16, and 5 X 104 cfu for E. coli AP. 
Results
A carboxyl terminalpeptidefrom human PF4 has antibacterial activity. Previous work had shown that the carboxyl terminus of human PF4 contained an amphipathic a-helical structural motif (18) . A peptide corresponding to amino acids 58 through 70, designated C13, was synthesized. Since the amphipathic a-helical motif is characteristic of a new group of antibacterial peptides ( 15) , C1 3 was examined for antibacterial activity. Antibacterial activity was determined in NHS and NHS H-NHS with bacteria that were grown with and without low levels of cefepime (Fig. 1) . A concentration of cefepime 448 Darveau et al. was chosen that had no effect on cell viability in the assay. In addition, an E. coli strain was selected that was completely resistant to the bactericidal action of serum. Under these conditions peptide C13 had a significant antibacterial effect (P < 0.05, two-sample t test for each peptide concentration examined) when bacteria grown in low levels ofcefepime were examined in NHS. In contrast to the data obtained in NHS, no antibacterial activity of peptide C13 was detected in the absence of cefepime or in H-NHS with or without cefepime. The role of peptide secondary structure in antibacterial activity was examined. Edmundson wheel projections (26) were used to design peptide analogues of C 13 that would be significantly less a-helical or amphipathic. Peptide analogue C13A was designed to disrupt the a-helical nature of the peptide by two proline replacements, whereas analogue C13B was designed to reduce the amphipathic nature of the peptide by exchanging charged residues and hydrophobic ones in two places. Antibacterial activity was examined in NHS on bacteria grown in low levels of cefepime. In contrast to peptide C 13, at a concentration of 200 tig/ml these peptides were not antibacterial (Table I) .
Peptide analogues ofCJ3 with increasedantibacterial activity. Edmundson wheel projections were used to design peptide analogues that differed in the predicted location and type of charge, degree of a-helicity, or number of helical turns. All analogues were designed to maintain both the a-helical and amphipathic nature of the peptide. A total of 40 different peptide analogues was synthesized. The objective was to determine if the unique antibacterial activity of peptide C 13 against cefepime-altered bacteria in NHS could be increased. Peptide analogues of C 13 were examined for potential antibacterial activity in NHS with bacteria grown in low levels of cefepime. The antibacterial potential of the analogues was determined by titrating the peptide analogue from a concentration which did not inhibit bacterial growth, up to 200 ,g/ml. Two peptide analogues yielded the most significant increase in antibacterial activity (Fig. 2 ). An increase of five amino acids predicted to generate another amphipathic a-helical loop at the carboxyl terminus and the replacement of proline with alanine at the amino terminus yielded analogue Cl 8H. This analogue demonstrated approximately one log increase in antibacterial activity compared to C 13 ( Fig. 2) . Another log increase in antibacterial activity was obtained when a glutamic acid residue was replaced with a lysine and two isoleucines were changed to leucines to form peptide analogue CI8G ( Fig. 2 ; see Table II for sequence of peptide analogues). Other experiments demonstrated that the two leucine to isoleucine substitutions (from C I 8H to C I 8G) did not significantly affect antibacterial activity (data not shown). peptide (jig/ml) Figure 2 . Antibacterial dose response of peptide C13 and two analogues in normal human serum. E. coli ATCC 25922 was grown to mid-log phase with 0.008 jg/ml ( Table II . The antibacterial activity of peptide analogue Cl 8G was greater than C 13 in all assay conditions. Although E. coli ATCC 25922 was completely resistant to NHS in the absence of peptide (see Fig. 1 and the legend to Fig. 2) , peptide analogue Cl 8G was significantly more potent in NHS when compared to H-NHS. In addition, although cefepime augmented the action ofpeptides C1 3 and Cl 8H, no difference in antibacterial activity was observed when Cl 8G was examined. In contrast to the increase in antibacterial activity, there was no increase in the hemolytic activity of C18G when compared to C 13. In summary, this analysis revealed that peptide Cl 8G was -80-fold more active than C1 3 when examined in NHS on bacteria incubated with or without low levels of cefepime.
Demonstration that complement augments peptide C18G antibacterial activity in human serum. The more potent antibacterial activity of peptide Cl 8G in NHS compared to H-NHS suggested that complement was required for optimal peptide activity in human serum. Therefore, the antibacterial activity ofpeptide C l 8G was further examined in sera that had been specifically depleted in complement protein C8. In two separate experiments the antibacterial activity of Cl 8G was determined in C8-deficient and C8-replenished sera with bacteria grown with and without low levels ofcefepime ( Fig. 3 ; only the results from experiments without cefepime are presented). In the absence of peptide Cl 8G, or when C8 was absent from the serum, bacteria grew in the assay. In contrast, when both C8 and peptide were present there was at least one log decrease from the bacterial input. These data demonstrate that the late components ofthe complement pathway greatly potentiate the antibacterial activity of Cl 8G in NHS. (Fig.r 4) .
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Next the ability of peptide analogue Cl 8G bo in combination with low levels of cefepime to from a lethal E. coli infection was examined (F separate experiments were performed with strai containing a group of mice that were treated w control as well as a group that was given a low level There was no significant difference (P > 0. 1 (Table III) , and separately to examine the combination of use C13. The Cl 8G and aztreonam, another f3-lactam antibiotic (Table IV) .
-corded for Mice were divided into four experimental treatment groups is significantly different from naturally occurring antibacterial peptides ( 15, 27) and represents a novel amino acid sequence forming an amphipathic a-helical motifthat contains antibacterial activity. The role ofthis motifin naturally occurring antibacterial peptides is currently under investigation by several different laboratories ( 15, 27, 28) . Modifications ofamino acid sequence (29) as well as chimeric (30) peptides are being studied in order to determine the potential clinical utility of this new class of antibacterials. In addition, antibacterial activity has been reported with peptides corresponding to amphipathic a-helical sequences in other naturally occurring proteins (31) (32) (33) . However, antibacterial activity was either too limited (33) or potentially toxic (due to lysis ofhuman red blood cells) (31, 32) to be clinically useful. In contrast, the results of this study demonstrated that C1 3 was antibacterial at concentrations of peptide that did not lyse human red blood cells. Peptide C13 therefore provided a unique amino acid sequence with clinically relevant antibacterial activity.
More potent analogues of C1 3 were designed and evaluated. Peptide C13 was similar to magainin 2 (14) in its requirement for NHS and low levels ofcefepime for optimal antibacterial activity. Therefore, the evaluation ofpeptides derived from C 13 for antibacterial activity was conducted in NHS with bacteria exposed to low levels of cefepime. This approach insured that those peptides that required the host immune system for optimal antibacterial activity would be identified. An initial evaluation of potentially new antibacterial agents in assay systems that employ human serum as contrasted to broth was proposed over 15 years ago (34) . However, perhaps because of the advent of more potent bactericidal antibiotics, little information has appeared in the literature concerning this approach (5) . An increased awareness of the role of the host immune system in the eradication ofbacterial infections (5), a need for improved therapy for neutropenic patients (1), as well as encouraging data obtained from in vitro and in vivo studies with magainin 2 (14) , prompted us to deviate from standard antibacterial drug discovery assays. In a study of 40 peptide analogues, two were identified that possessed significant increases in antibacterial activity. Extending the length of peptide C13 and the substitution of a negative with a positive charge resulted in peptide Cl 8G which was 80-fold more active than C1 3.
Studies in sera depleted of complement protein C8 confirmed that peptide analogue Cl 8G required complement for optimal peptide activity. This is similar to magainin 2 (14) and other cationic peptides (35, 36) that have been shown to render bacteria more susceptible to serum bactericidal activity. Studies with NHS and H-NHS with several bacterial strains are consistent with a strong complement requirement for optimal antibacterial activity of the peptide. The addition of low levels of cefepime augmented the peptide antibacterial action for some strains but not others. Independently, low levels of cefepime have been shown to increase bacterial susceptibility to serum by allowing more effective C5b-9 deposition on the altered bacterial cell surface ( 12) . Initial studies show that addition ofpeptide Cl 8G results in significantly more COb-9 deposition (data not shown); however, the molecular interaction between the cefepime altered bacterial cell, antimicrobial peptide, and complement remains unclear. Peptide C18X, an all D analogue, showed similar antibacterial activity in vitro (data not shown) as well as in mouse protection experiments. This indicates that those aspects of peptide action that require serum complement for optimal activity do not involve specific enzymes or chiral receptors. Wade et al. ( 15) have shown that D enantiomers of three naturally occurring peptide antibiotics retain antibacterial activity. A possible hypothesis is that pep- We explored the possibility that other closely related sequences would be antibacterial with serum complement. Peptides derived from the amphipathic a-helical motiffound at the carboxyl terminus of an interferon-inducible protein designated IP 10 (39) were synthesized. This cytokine is a member of the same IL-8 cytokine family, as is PF4 (40) . The carboxyl terminus of IP 10 has been postulated to be cleaved (39) . This suggested to us the potential for an endogenous antibacterial peptide which may serve as an adjunct to serum mediated killing. Serum factors that augment complement-mediated killing have been postulated by others (41, 42) . However, antibacterial activity was not found when three different peptide sequences from the carboxyl terminus of IP 10 were examined in our assay (data not shown). In a related finding, other peptide analogues of C13 were also found to be inactive, although based on Edmundson wheel projections they should have maintained the correct secondary structure (data not shown). Further studies will be necessary to determine the relationship between secondary structure, amino acid sequence, and antibacterial activity for this unique group of antibacterial peptides.
In vivo protection studies with E. coli demonstrated that peptide Cl 8G when combined with low levels ofcefepime was able to significantly protect mice from a lethal infection. Significant protection was also observed when peptide Cl 8G was coadministered with aztreonam, another f3-lactam antibiotic. Although other t-lactam antibiotics were not employed in this study, earlier work ( 12, 14) would indicate that this class of antibiotics but not aminoglycosides nor quinolones augment bacterial killing by serum and peptide. The animal experiments are similar to those previously conducted with magainin 2 (14) where low levels of cefepime were employed to mimic clinical failure ofthe antibiotic. Administration oflow levels of antibiotic were necessary to determine if the peptide would augment protection. Clinically, antibiotics may not reach sufficient concentration at their bacterial targets due to both bacterial resistance and/or impaired drug access, or the existence of local environmental conditions that are antagonistic to antibiotic action. Insufficient antibiotic concentrations may be more effective in the immunosufficient host where injured bacteria are removed by the host defense system. These studies further support the notion ( 14) that augmentation of antibiotic therapy with peptides or other agents that take advantage ofantibiotic-altered bacteria may be beneficial for the neutropenic patient.
